Chai Discovery, a San Francisco, CA-based AI firm that predicts and reprograms the interactions between biochemical molecules to speed up life-changing therapeutics, raised $70m in Sequence A financing.
The spherical was led by Menlo Ventures, together with funding from their Anthology Fund, a joint partnership with Anthropic to establish and again promising AI firms, with participation from new buyers Yosemite, DST International Companions, SV Angel, Avenir, DCVC, and others, and current buyers Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam, amongst others. Mikael Dolsten M.D., PhD., the previous Pfizer Chief Scientific Officer liable for advancing 150 molecules into medical trials and delivering 36 permitted medicines, is becoming a member of the corporate’s board of administrators.
The corporate intends to make use of the funds to additional develop the Chai platform, making use of it towards beforehand inaccessible targets, and onboarding choose companions.
Based in 2024 by Joshua Meier (ex AI drug discovery agency Absci; Fb AI; OpenAI), Jack Dent (ex Eng and Product chief at Stripe), and AI researchers Matthew McPartlon and Jacques Boitreaud, Chai Discovery builds frontier synthetic intelligence to foretell and reprogram the interactions between biochemical molecules.
Final yr, the corporate closed a $30 million seed spherical led by Thrive Capital, OpenAI, and Dimension. Quickly after, they launched Chai-1, an open-source basis mannequin for molecular construction prediction that performs on the state-of-the-art
Final month, the crew launched Chai‑2 breakthrough, delivering totally de novo antibody design with a near-20% hit price. When inputting solely the goal antigen and epitope, Chai‑2 can generate profitable binders from scratch in opposition to all kinds of targets.
FinSMEs
06/08/2025
